HomeResearch & Knowledgeback to Homeback to Research & KnowledgeHerceptin & Roche in India: The battle for life-saving treatment (B)back to

Case Study

Herceptin & Roche in India: The battle for life-saving treatment (B)

By Michael Yaziji and Lisa Simone Duke

4 pages

December 2014

Order this case study

Reference: IMD-7-1635

This case series looks at the actions taken by NGOs, local campaigners and the Indian government, against Roche over its patent for a breast cancer drug “Trastuzumab”, otherwise known as “Herceptin”, Herceptin was an expensive but highly effective treatment for some types of breast cancer and campaigners were vocal in arguing that in emerging markets, such as India, it was beyond the means of the majority of the population. Case B covers the period and actions from January 2013 to mid-2014. Sensing that it would not receive a renewal of its patent protection from the Indian government, in August 2013, Roche decided not to pursue its patent in India. The government fast-tracked local companies to produce biosimilars. In January 2014, the local biosimilar was launched onto the marketplace but it was only 25% less expensive than Herceptin. In an unusual twist, a month later, the Delhi High Court granted Roche an injunction against the generic manufacturers comparing their products to Herceptin in marketing campaigns.

Learning Objective

This case series looks to understand how NGOs and local campaigners can affect a company’s ability to market its products or operate in emerging markets.

Keywords

Pharmaceuticals, Global Business, Emerging Market, Intellectual Property Rights, Patent Protection, Non-Governmental Organization, Non-Governmental Organization Campaign, Free Trade Agreement, Oncology, Generic Drug

Settings

Asia, India
Roche, Healthcare, Pharmaceuticals
2013-2014

Type

Published Sources

Available Languages

English

IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]

IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Keep reading

Article

Optimizing omnichannel assortments and inventory provisions under the multichannel attraction model

Assortment optimization presents a complex challenge for retailers, as it depends on numerous decision factors. Changes in assortment can result in demand redistribution with multi-layered consequences. This complexity is even more pronounced for ...

General Management

By Andrey Vasilyev, Sebastian Maier and Ralf W. Seifert

in European Journal of Operational Research

August 2025, vol. 324, no. 3, pp. 799-813, https://doi.org/10.1016/j.ejor.2025.01.035

Article

Diversity In Leadership - Reinforcing Values

True transformation comes from embedding diversity in leadership values, not compliance. Leaders must foster safe spaces and model vulnerability.

Diversity and Equity and Inclusion

By Silke Mischke

in I by IMD

Article

Strategic use of AI in healthcare and pharma drives market advantage. Here’s how - IbyIMD

AI is fundamental to the competitive strategies of the most advanced healthcare and pharmaceutical firms. Here is how they are adopting AI to be data-driven leaders.

Innovation Strategy Technology Management

By Tomoko Yokoi and Michael R. Wade

in I by IMD

Article

Chips Act 2.0 - Digital Race - Europe

Former French finance minister Bruno Le Maire says Europe needs to act urgently to secure the semiconductor supply or face relegation to the global slow lane.

This much I know: 9 leadership lessons from global CEOs - IbyIMD

From absorbing stress to finding your authentic voice, nine leaders of global companies share the wisdom that has helped them excel in their roles.

By Jean-François Manzoni

in I by IMD

Article

The energy trilemma: why it pays to get the balance right - IbyIMD

Dealing with the conflicting demands of price, sustainability, and security of energy supplies is challenging, but it’s a useful way to assess your firm’s resilience and agility.

By Ann-Christin Andersen and Karl Schmedders

in I by IMD

Article

Use AI To Become A Better Thinker - AI Usage

Professionals who use AI in a disciplined way to compound their cognitive thinking over time will be the long-term winners. Michael Watkins explains how to make AI a cognitive superpower rather than a crutch

By Michael D. Watkins

in I by IMD

Article

Making good use of a blackout - Electricity Systems

The Spanish blackout of April 2025 is an opportunity to strengthen electricity systems that have higher shares of renewables and should not be used as an excuse to slow down the energy transition.

Sustainability

By Cédric Philibert

in I by IMD

Case Study

HP Amplify Impact A: Channeling partners for change

Sustainability Leadership

By Heather Cairns-Lee, Julia Katharina Binder and Valerie Keller-Birrer

Optimizing omnichannel assortments and inventory provisions under the multichannel attraction model

By Andrey Vasilyev Sebastian Maier and Ralf W. Seifert
in European Journal of Operational Research August 2025, vol. 324, no. 3, pp. 799-813, https://doi.org/10.1016/j.ejor.2025.01.035

Summary

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Related topics

General Management

Browse all topics

Strategic use of AI in healthcare and pharma drives market advantage. Here’s how - IbyIMD

By Tomoko Yokoi and Michael R. Wade
in I by IMD

Summary

AI is fundamental to the competitive strategies of the most advanced healthcare and pharmaceutical firms. Here is how they are adopting AI to be data-driven leaders.

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Related topics

Innovation

Strategy

Technology Management

Browse all topics

HP Amplify Impact B: From launch to legacy

By Julia Katharina Binder and Heather Cairns-Lee
Case reference: IMD-2695

Summary

The B case outlines how, by early 2025, Isabella Phoenix's initial vision for HP's Amplify Impact sustainability program had grown into a global initiative involving 4,800 partners in 48 countries. The program surpassed its goals, enrolling 59 of HP partners vs. a 50 target and contributing to billions of dollars in sustainability-influenced sales. Key to its success were tools like a clear self-assessment, a rich resource hub and a focus on voluntary engagement rather than financial incentives building true partnerships instead of transactional relationships. Partners gained credibility and competitive advantage, and the program was supported strongly by HP leadership and recognized with major awards. However, as Phoenix and senior leaders prepared to leave the company, the program faced challenges: rising competitor initiatives, shifting political attitudes toward ESG and internal leadership transitions. The central question became whether HP could sustain and evolve Amplify Impact's momentum and values in this uncertain environment.

Reference IMD-2695

Organization Hewlett-Packard

Industry Information Technology

Available Languages English

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Related topics

Sustainability

Leadership

Browse all topics

HP Amplify Impact A: Channeling partners for change

By Heather Cairns-Lee Julia Katharina Binder and Valerie Keller-Birrer
Case reference: IMD-2681 ©2025

Summary

The A case in this two-part series outlines the challenges Isabella Phoenix faced in designing a global sustainability program for HP's vast network of channel partners in just 12 weeks with only one team member and limited resources. The initiative aimed to help embed sustainability in HP global partners' strategies, many of whom lacked the resources or expertise to tackle sustainability alone. Phoenix faced the dual challenge of inspiring internal buy-in and engaging thousands of independent partners many of them small or midsize businesses with limited capacity. The voluntary program, built around HP's Sustainable Impact priorities of climate action, human rights, and digital equity and community, aimed to educate and empower partners without relying on traditional financial incentives. Instead, it encouraged commitment through practical tools and self-assessments and integrating sustainability into commercial deals. Despite the absence of rebates or rewards, the program sought to transform HP's ecosystem into a purpose-driven movement, proving that shared values and long-term impact could unite a diverse, global network.

Reference IMD-2681

Organization Hewlett-Packard

Industry Information Technology

Available Languages English

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Related topics

Sustainability

Leadership

Browse all topics